Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC mutation
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC rearrangement + BCL2 rearrangement (22)
MYC rearrangement + BCL6 rearrangement (9)
MYC rearrangement (7)
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement (6)
MYC translocation (4)
MYC translocation + BCL2 translocation (3)
EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)
MYC translocation + BCL6 translocation (1)
MYC translocation + BCL6 translocation + BCL2 translocation (1)
MYC rearrangement + BCL2 rearrangement+ BCL6 rearrangement (0)
MYC rearrangement + BCL2 rearrangement (22)
MYC rearrangement + BCL6 rearrangement (9)
MYC rearrangement (7)
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement (6)
MYC translocation (4)
MYC translocation + BCL2 translocation (3)
EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)
MYC translocation + BCL6 translocation (1)
MYC translocation + BCL6 translocation + BCL2 translocation (1)
MYC rearrangement + BCL2 rearrangement+ BCL6 rearrangement (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC mutation
Colorectal Cancer
MYC mutation
Colorectal Cancer
regorafenib
Resistant: C3 – Early Trials
regorafenib
Resistant
:
C3
regorafenib
Resistant: C3 – Early Trials
regorafenib
Resistant
:
C3
MYC mutation
Diffuse Large B Cell Lymphoma
MYC mutation
Diffuse Large B Cell Lymphoma
CUDC-907
Sensitive: C3 – Early Trials
CUDC-907
Sensitive
:
C3
CUDC-907
Sensitive: C3 – Early Trials
CUDC-907
Sensitive
:
C3
MYC mutation
HER2 Positive Breast Cancer
MYC mutation
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
trastuzumab + atezolizumab + pertuzumab
Resistant
:
C3
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
trastuzumab + atezolizumab + pertuzumab
Resistant
:
C3
MYC mutation
Triple Negative Breast Cancer
MYC mutation
Triple Negative Breast Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MYC mutation
Diffuse Large B Cell Lymphoma
MYC mutation
Diffuse Large B Cell Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login